The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1681
ISSUE1681
July 24, 2023
Sotagliflozin (Inpefa) for Heart Failure
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Sotagliflozin (Inpefa) for Heart Failure
July 24, 2023 (Issue: 1681)
The FDA has approved sotagliflozin (Inpefa –
Lexicon), an oral sodium-glucose cotransporter
1 and 2 (SGLT1/2) inhibitor, to reduce the risk of
hospitalization for heart failure (HF), urgent HF visits,
and cardiovascular death in adults with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.